Skip to main content
padlock icon - secure page this page is secure

Beta‐blockers are under‐prescribed in patients with chronic obstructive pulmonary disease and co‐morbid cardiac disease

Buy Article:

$52.00 + tax (Refund Policy)

The use of beta‐blockers in patients with chronic obstructive pulmonary disease and co‐morbid cardiovascular disease is controversial, despite increasing evidence to support their use as safe and efficacious. This study retrospectively assessed the rates of beta‐blocker prescription in patients admitted to two Australian tertiary hospitals for acute exacerbation of chronic obstructive pulmonary disease. This revealed that less than half of patients (45%) with known cardiac indications were receiving beta‐blocker therapy, evident across all degrees of airways disease severity. Further work is needed to ensure that medical management of this patient group is optimised.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: COPD; beta‐blocker; cardiovascular disease; chronic obstructive pulmonary disease; prescription

Document Type: Research Article

Publication date: November 1, 2016

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more